[go: up one dir, main page]

AU2023414924A1 - Heterocyclic and heteroaryl compounds as inhibitors of nlrp3 - Google Patents

Heterocyclic and heteroaryl compounds as inhibitors of nlrp3 Download PDF

Info

Publication number
AU2023414924A1
AU2023414924A1 AU2023414924A AU2023414924A AU2023414924A1 AU 2023414924 A1 AU2023414924 A1 AU 2023414924A1 AU 2023414924 A AU2023414924 A AU 2023414924A AU 2023414924 A AU2023414924 A AU 2023414924A AU 2023414924 A1 AU2023414924 A1 AU 2023414924A1
Authority
AU
Australia
Prior art keywords
nlrp3
heterocyclic
inhibitors
heteroaryl compounds
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023414924A
Inventor
Rauful Alam
Lauren BEJCEK
Hua Gong
Handoko
Seyedmorteza HOSSEYNI
Eduardo HUARTE
Jing Li
Yao Liu
Erica N. PARKER
Meenu PILLAI
Ettore RASTELLI
Nadiya Sydorenko
Matthew G. WOLL
Nanjing Zhang
Xiaoyan Zhang
Tianyi ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2023414924A1 publication Critical patent/AU2023414924A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023414924A 2022-12-30 2023-12-29 Heterocyclic and heteroaryl compounds as inhibitors of nlrp3 Pending AU2023414924A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263477864P 2022-12-30 2022-12-30
US63/477,864 2022-12-30
US202363503344P 2023-05-19 2023-05-19
US63/503,344 2023-05-19
PCT/US2023/086506 WO2024145623A1 (en) 2022-12-30 2023-12-29 Heterocyclic and heteroaryl compounds as inhibitors of nlrp3

Publications (1)

Publication Number Publication Date
AU2023414924A1 true AU2023414924A1 (en) 2025-07-03

Family

ID=90097580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023414924A Pending AU2023414924A1 (en) 2022-12-30 2023-12-29 Heterocyclic and heteroaryl compounds as inhibitors of nlrp3

Country Status (6)

Country Link
EP (1) EP4642784A1 (en)
JP (1) JP2026502905A (en)
CN (1) CN120826402A (en)
AU (1) AU2023414924A1 (en)
MX (1) MX2025007519A (en)
WO (1) WO2024145623A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
TW202502344A (en) * 2023-06-02 2025-01-16 美商默沙東有限責任公司 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2024251073A1 (en) * 2023-06-03 2024-12-12 成都赜灵生物医药科技有限公司 Pyridazine compound and use thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255895A1 (en) * 2020-04-15 2022-12-15 Janssen Pharmaceutica Nv Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway
CN115433163A (en) * 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 NLRP3 inflammasome inhibitor and application thereof

Also Published As

Publication number Publication date
CN120826402A (en) 2025-10-21
EP4642784A1 (en) 2025-11-05
WO2024145623A1 (en) 2024-07-04
JP2026502905A (en) 2026-01-27
MX2025007519A (en) 2025-09-02

Similar Documents

Publication Publication Date Title
AU2023414924A1 (en) Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
EP3990448A4 (en) Heterocyclic compounds as inhibitors of kras g12c
CA3260468A1 (en) Compounds as inhibitors of axl
AU2024255473A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
EP4112052A4 (en) Application of n-substituted pyridyl benzisoselenazolone compound
EP4263520A4 (en) Heterocyclic inhibitors of pcsk9
CA3277202A1 (en) Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
EP4322947A4 (en) Heteroaryl compounds as inhibitors of rip2 kinase, composition and application thereof
EP4144734A4 (en) Application of heterocyclic compound
HK40092811A (en) Preparation and application method of heterocyclic compound as kras inhibitor
CA3280638A1 (en) Inhibitors of nlrp3
CA3288941A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
HK40109676A (en) Inhibitors of nlrp3
HK40118914A (en) Heterocyclic compounds and methods of use
CA3282949A1 (en) Heterocyclic compounds and methods of use thereof
HK40099180A (en) Inhibitors of nlrp3 inflammasome
HK40089983A (en) Substituted heteroaryl compounds useful as inhibitors of tlr9
HK40117000A (en) N-oxide inhibitors of nlrp3 inflammasome
HK40111748A (en) Use of heterocyclic compound
AU2020904774A0 (en) Heterocyclic inhibitors of PCSK9
CA3291841A1 (en) Novel compounds as cyp11a1 inhibitors and methods of use thereof
HK40105358A (en) Crystal form of pyrimidine heterocyclic compound and preparation method therefor
CA3271284A1 (en) Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof
HK40119797A (en) 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
CA3261944A1 (en) Methods of preparation of heterocyclic compounds